Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.
The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.
The company's shares closed more than 4% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。